December 2025 - Page 7 of 12

On-site from ESMO Asia | Professor Liangyou Gu: Disitamab Vedotin Plus Immunotherapy Brings New Hope for Adjuvant Treatment of UTUC

By Mourabit Halima 2025.12.18

Editor’s Note The incidence of upper tract urothelial carcinoma (UTUC) in China is significantly higher than in Western countries. Although radical nephroureterectomy remains the gold standard for treatment, a substantial…

Professor Peng Zhang: The HOPE Program Paves the Way for Bladder-Preserving Care in Urothelial Carcinoma

By Mourabit Halima 2025.12.18

Editor’s Note: From November 10–16, 2025, the 9th West China Urologic Oncology Tianfu Academic Conference and the 11th Academic Annual Meeting on Urologic and Male Genitourinary Tumors of the Sichuan…

ASH China Voice | Professors Lu Peihua / Zhang Xian: CD7 CAR-T Therapy Significantly Improves Outcomes in R/R CD7-Positive Hematologic Malignancies

By Peter W. PENG 2025.12.18

At the 67th Annual Meeting of the American Society of Hematology (ASH), Professor Lu Peihua and Professor Zhang Xian from Lu Daopei Hospital presented a large-scale clinical study of a…

ASH Hot Topics | Prof. Yang Linhua: Anti-BAFF-R mAb Advances ITP from Symptom Control to Disease Modification

By Mourabit Halima 2025.12.17

Immune thrombocytopenia (ITP) is an immune-mediated thrombocytopenic disorder that can lead to severe bleeding and markedly impair quality of life. At the 67th Annual Meeting of the American Society of…

ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

By Mourabit Halima 2025.12.17

On December 6 (local time), a highly anticipated special session on the ASH Clinical Practice Guidelines on Myelofibrosis was successfully held during the American Society of Hematology (ASH) Annual Meeting.…

ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

By Peng Longmei 2025.12.17

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international…

ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

By Mourabit Halima 2025.12.17

At this year’s Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang Haiwen from the First Affiliated Hospital of Soochow University reported multiple important…

ASH China Voice | Professor Chengcheng Fu’s Team: Innovative Therapies and MRD-Driven Strategies Advance Clinical Progress in Multiple Myeloma

By Peter W. PENG 2025.12.16

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, bringing together the latest global research and clinical advances…

ASH Voices from China丨Deyan Liu & Xiaohong Liu: Real-World HSCT Outcomes in 82 Patients with SIL::TAL1-Positive T-ALL/LBL

By Peng Longmei 2025.12.16

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the largest and most influential international congress…

ASH Hot Take | Prof. Huaqian Wang: A New Perspective on Low-Risk MDS – Clinical Value of Shortened Hypomethylating Therapy

By Mourabit Halima 2025.12.16

Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by marked heterogeneity and complex prognosis. While treatment of intermediate- and high-risk disease remains challenging, there is also considerable…